Elbit Med Tech (EMTC) - Total Liabilities

Latest as of December 2022: ILA522.00K ILA ≈ $1.40K USD

Based on the latest financial reports, Elbit Med Tech (EMTC) has total liabilities worth ILA522.00K ILA (≈ $1.40K USD) as of December 2022. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore EMTC long-term investment intensity to see how much of total assets are deployed in long-term investments.

Elbit Med Tech - Total Liabilities Trend (2008–2022)

This chart illustrates how Elbit Med Tech's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Elbit Med Tech's balance sheet.

Elbit Med Tech Competitors by Total Liabilities

The table below lists competitors of Elbit Med Tech ranked by their total liabilities.

Company Country Total Liabilities
Tasfoods Ltd
AU:TFL
Australia AU$18.89 Million
Invinity Energy Systems PLC
LSE:IES
UK GBX14.61 Million
Severfield PLC
LSE:SFR
UK GBX216.52 Million
Smartfren Telecom Tbk
JK:FREN
Indonesia Rp21.74 Trillion
Luminar Technologies Inc. Class A
NASDAQ:LAZRQ
USA $608.34 Million
Fuse Cobalt Inc
V:FUSE
Canada CA$271.68K
Gaucho Group Holdings Inc
NASDAQ:VINO
USA $10.85 Million

Liability Composition Analysis (2008–2022)

This chart breaks down Elbit Med Tech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Elbit Med Tech to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.33 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.02 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.02 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Elbit Med Tech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Elbit Med Tech (2008–2022)

The table below shows the annual total liabilities of Elbit Med Tech from 2008 to 2022.

Year Total Liabilities Change
2022-12-31 ILA522.00K
≈ $1.40K
-7.45%
2021-12-31 ILA564.00K
≈ $1.51K
-98.47%
2020-12-31 ILA36.97 Million
≈ $99.12K
-26.77%
2019-12-31 ILA50.48 Million
≈ $135.34K
+15.99%
2018-12-31 ILA43.52 Million
≈ $116.69K
+2.47%
2017-12-31 ILA42.48 Million
≈ $113.87K
+14.23%
2016-12-31 ILA37.18 Million
≈ $99.69K
+9.35%
2015-12-31 ILA34.00 Million
≈ $91.16K
+4.42%
2014-12-31 ILA32.56 Million
≈ $87.31K
-3.70%
2013-12-31 ILA33.82 Million
≈ $90.66K
-41.03%
2011-12-31 ILA57.35 Million
≈ $153.75K
+65.68%
2010-12-31 ILA34.61 Million
≈ $92.80K
-78.13%
2009-12-31 ILA158.28 Million
≈ $424.35K
-14.28%
2008-12-31 ILA184.65 Million
≈ $495.03K
--

About Elbit Med Tech

TA:EMTC Israel Healthcare Equipment & Supplies
Market Cap
$5.52 Million
ILA2.06 Billion ILA
Market Cap Rank
#30465 Global
#444 in Israel
Share Price
ILA22.20
Change (1 day)
-7.50%
52-Week Range
ILA18.40 - ILA28.50
All Time High
ILA185.50
About

Elbit Medical Technologies Ltd, an investment holding company, engages in the research, development, production, and marketing of magnetic and focused imaging equipment in the United States, Europe, and internationally. The company is developing a magnetic resonance imaging guided focused ultrasound treatment equipment to address various oncology and gynecology indications, as well as neurologica… Read more